Introduction Rare diseases, as classified by the FDA and EMA, are conditions that affect fewer than 200,00 people in the US1 or fewer than five in 10,000 people in the EU2. Because of these small populations, rare diseases often face unique – and some respects potentially more significant – hurdles in implementing clinical trials, thus […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!